Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...

Dakota Wealth Management cut its position in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 13.4% during the fourth ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), reported a significant transaction involving ...

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $29.72, signifying a -0.3% move from its prior day's close.

Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Citigroup has recently reduced Hims & Hers Health Inc (HIMS) stock to Sell rating, as announced on January 10, 2025, according to Finviz. Earlier, on January 7, 2025, BTIG Research had initiated the ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...